The estimated Net Worth of Joanne Smith Farrell is at least $185 Tisíc dollars as of 5 January 2021. Ms. Farrell owns over 1,329 units of Bluebird bio Inc stock worth over $11,953 and over the last 5 years she sold BLUE stock worth over $172,843. In addition, she makes $0 as Chief Business Officer at Bluebird bio Inc.
Sign up
Ms. Farrell BLUE stock SEC Form 4 insiders trading
Joanne has made over 13 trades of the Bluebird bio Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 1,329 units of BLUE stock worth $59,871 on 5 January 2021.
The largest trade she's ever made was selling 1,329 units of Bluebird bio Inc stock on 5 January 2021 worth over $59,871. On average, Joanne trades about 229 units every 26 days since 2020. As of 5 January 2021 she still owns at least 20,609 units of Bluebird bio Inc stock.
You can see the complete history of Ms. Farrell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Joanne Smith-Farrell biography
Joanne M. Smith-Farrell Ph.D. serves as Chief Business Officer of the Company. Dr. Smith-Farrell has served as our Chief Business Officer since April 2019, and as our oncology franchise leader since September 2017. Prior to this role, Dr. Smith-Farrell served as our Senior Vice President, Corporate Development and Strategy since April 2017. From January 2014 to March 2017, Dr. Smith-Farrell served as Vice President, Business Development Transactions at Merck & Co., Inc. where she led the team that structured, negotiated, and executed business development transactions supporting Merck Research Labs. From September 2007 to January 2014, Dr. Smith-Farrell served as Vice President of Strategic Transactions at Pfizer, Inc. Dr. Smith-Farrell holds a Ph.D. in Physics from the Catholic University of America, and a B.S. in Physics and Mathematics from Vanderbilt University. She was also a Fellow in Biomedical & Chemical Engineering at The Harvard-MIT Division for Health Science & Technology (Dr. Robert Langer’s Lab) where she received the NIH National Service Award in Research.
How old is Joanne Farrell?
Joanne Farrell is 50, she's been the Chief Business Officer of Bluebird bio Inc since 2019. There are 9 older and 13 younger executives at Bluebird bio Inc. The oldest executive at Bluebird bio Inc is Wendy Dixon, 64, who is the Independent Director.
What's Joanne Farrell's mailing address?
Joanne's mailing address filed with the SEC is C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE, MA, 02142.
Insiders trading at Bluebird bio Inc
Over the last 11 years, insiders at Bluebird bio Inc have traded over $130,743,125 worth of Bluebird bio Inc stock and bought 6,469 units worth $399,874 . The most active insiders traders include Steven Gillis, John Maraganore a Robert I Tepper. On average, Bluebird bio Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,033. The most recent stock trade was executed by Thomas J Klima on 3 June 2024, trading 3,834 units of BLUE stock currently worth $3,719.
What does Bluebird bio Inc do?
we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.
What does Bluebird bio Inc's logo look like?
Complete history of Ms. Farrell stock trades at Bluebird bio Inc
Bluebird bio Inc executives and stock owners
Bluebird bio Inc executives and other stock owners filed with the SEC include:
-
Nick Leschly,
President, Chief Executive Officer, Director -
William Baird,
Chief Financial Officer -
David Davidson,
Chief Medical Officer -
Philip Gregory,
Chief Scientific Officer -
Jason Cole,
Chief Operating Officer and Legal Officer, Secretary -
Nick Leschly,
Pres & Director -
William Sellers,
Independent Director -
William D. Baird III,
Principal Financial & Accounting Officer -
Daniel Lynch,
Independent Chairman of the Board -
Jason F. Cole Esq.,
Chief Strategy & Financial Officer -
Thomas J. Klima,
Chief Commercial Officer & COO -
Mark Vachon,
Independent Director -
David Schenkein,
Independent Director -
Wendy Dixon,
Independent Director -
John Agwunobi,
Independent Director -
Ingrid Goldberg,
VP, Investor Relations -
Denice Torres,
Director -
Joanne Smith-Farrell,
Chief Business Officer -
Alison Finger,
Chief Commercial Officer -
Katy Burnett,
Interim Principal Accounting Officer -
Richard Colvin M.D., Ph.D.,
Chief Medical Officer -
Andrea Walton,
Chief People Officer -
Katherine Edna Breedis C.F.A., CMT,
Interim CFO, Principal Financial Officer & Principal Accounting Officer -
Anne-Virginie Eggimann M.Sc.,
Chief Regulatory Officer -
Melissa Bonner,
Sr. VP of Research -
Dr. Liviu Niculescu M.D., Ph.D.,
Sr. VP of Global Medical Affairs -
Sarah Alspach,
Chief Communications Officer -
Kathleen A. Wilkinson,
Chief People Officer -
Elizabeth Pingpank,
Director of Corp. Communications -
Helen C. Fu,
Sr. VP, Gen. Counsel & Sec. -
Jessica Whitten,
VP, Global Controller & Chief Accounting Officer -
Kasra Kasraian,
Sr. VP of Technical Devel. & Operations -
Gina R. Consylman CPA,
Chief Financial Officer -
Andrew Obenshain,
Pres, CEO & Director -
John Maraganore,
Director -
James Mandell,
Director -
Susanna Gatti High,
Chief Operating Officer -
Eric Sullivan,
Principal Accounting Officer -
Andrew Obenshain,
President and CEO -
Douglas Melton,
-
Mary Lynne Hedley,
Director -
Kory James Wentworth,
Principal Accounting Officer -
Thomas J Klima,
See Remarks -
Charlotte Jones Burton,
-
Axel Polack,
Director -
Geert Jan Mulder,
Director -
Christopher Krawtschuk,
Chief Financial Officer -
Mitchell H. Finer,
Chief Scientific Officer -
James M. Detore,
Chief Financial Officer -
Venture Fund Vii Lparch Ven...,
-
Robert I Tepper,
Director -
Rock Ventures Lptrv Gp, Llc...,
-
Linda Bain,
VP, Fin. & Business Operations -
Rock Ventures Lp Third Rock...,
-
Jeffrey T. Walsh,
Chief Strategy Officer -
Steven Gillis,
Director -
Richard A. Paulson,
-
Gina Consylman,
Chief Financial Officer -
Anne Virginie Eggimann,
Chief Regulatory Officer -
Jessica Whitten,
Chief Accounting Officer -
Marcela V. Maus,
Director -
Sarah Js Glickman,
Director -
Ramy Ibrahim,
Director -
Joseph Vittiglio,
Chief Business & Legal Officer -
Richard A Colvin,
Chief Medical Officer -
Najoh Tita Reid,
-
Elisabeth Leiderman,
-
Michael Cloonan,
-
O. James Sterling,
Chief Financial Officer